Howard; Maureen

Patent Applications and Registrations

Patent applications and USPTO patent grants for Howard; Maureen.The latest application filed is for "methods for achieving therapeutically effective doses of anti-cd47 agents".

Company Profile

3.10.15

Howard; Maureen - Los Altos Hills CA
Howard; Maureen - Los Altos CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods For Achieving Therapeutically Effective Doses Of Anti-cd47 Agents App 20220289845 - Willingham; Stephen ; et al.	2022-09-15
Methods For Achieving Therapeutically Effective Doses Of Anti-cd47 Agents App 20220251199 - Willingham; Stephen ; et al.	2022-08-11
Methods For Achieving Therapeutically Effective Doses Of Anti-cd47 Agents App 20210380689 - Willingham; Stephen ; et al.	2021-12-09
Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody Grant 11,136,391 - Willingham , et al. October 5, 2	2021-10-05
Compositions for achieving therapeutically effective doses of anti-CD47 agents Grant 11,104,731 - Willingham , et al. August 31, 2	2021-08-31
Methods For Achieving Therapeutically Effective Doses Of Anti-cd47 Agents App 20210079093 - Willingham; Stephen ; et al.	2021-03-18
Methods For Achieving Therapeutically Effective Doses Of Anti-cd47 Agents App 20190218289 - Willingham; Stephen ; et al.	2019-07-18
Methods for achieving therapeutically effective doses of anti-CD47 agents Grant 10,301,387 - Willingham , et al.	2019-05-28
Methods For Achieving Therapeutically Effective Doses Of Anti-cd47 Agents App 20170145096 - Willingham; Stephen ; et al.	2017-05-25
Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer Grant 9,623,079 - Willingham , et al. April 18, 2	2017-04-18
Methods for Achieving Therapeutically Effective Doses of anti-CD47 Agents App 20160008429 - Willingham; Stephen ; et al.	2016-01-14
Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof Grant 8,637,043 - Schall , et al. January 28, 2	2014-01-28
Reagents That Bind Ccx-ckr2 App 20100278820 - Howard; Maureen ; et al.	2010-11-04
Methods and Compositions For Modulating Angiogenesis App 20100247540 - Burns; Jennifer ; et al.	2010-09-30
Antibodies that bind CCX-CKR2 Grant 7,678,891 - Howard , et al. March 16, 2	2010-03-16
Compositions for inducing an immune response Grant 7,361,329 - Schall , et al. April 22, 2	2008-04-22
Reagents that bind CCX-CKR2 App 20060257410 - Howard; Maureen ; et al.	2006-11-16
Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof App 20060034863 - Schall; Thomas J. ; et al.	2006-02-16
Methods and compositions for modulating angiogenesis App 20050214287 - Burns, Jennifer ; et al.	2005-09-29
Methods and compositions for inducing an immune response App 20030215460 - Schall, Thomas J. ; et al.	2003-11-20
Methods and compositions for inducing an immune response App 20030108515 - Schall, Thomas J. ; et al.	2003-06-12
Chemokine receptor peptide vaccines for treatment and prevention of diabetes App 20010006942 - Howard, Maureen ; et al.	2001-07-05
Chemokine receptor peptide for inducing an immune response Grant 6,171,590 - Howard , et al. January 9, 2	2001-01-09
Use of an interleukin-10 antagonist to treat a B cell mediated autoimmune disorder Grant 5,837,232 - De Waal Malefyt , et al. November 17, 1	1998-11-17

Company Registrations

NCAGE Code	52FS3	HOWARD, MAUREEN
CAGE Code	52FS3	HOWARD, MAUREEN
DUNS	796498272	HOWARD, MAUREEN
SEC	0001423281	Howard Maureen

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.